128940.KS
Hanmi Pharm. Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 460,500.00
−2.85%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1655.5B | 1547.5B | 1495.5B | 1490.9B | 1331.5B |
| Cost of Revenue | 668.9B | 663.1B | 678.5B | 661.6B | 613.0B |
| Gross Profit | 986.6B | 884.4B | 817.0B | 829.2B | 718.6B |
| Operating Expenses | |||||
| R&D Expense | 163.4B | 195.8B | 178.9B | 181.8B | 154.3B |
| SG&A Expense | 194.2B | 225.9B | 233.7B | 248.2B | 233.6B |
| General & Admin Expense | 27.5B | 66.4B | 62.3B | 65.2B | 61.3B |
| Selling & Marketing Expense | 166.6B | 159.5B | 171.4B | 183.0B | 172.3B |
| Other Expenses | 349.9B | 238.8B | 188.3B | 178.5B | 172.5B |
| Total Operating Expenses | 707.5B | 660.5B | 600.9B | 608.6B | 560.5B |
| Cost and Expenses | 1376.4B | 1323.7B | 1279.3B | 1270.2B | 1173.5B |
| Operating Income (EBIT) | 279.0B | 223.9B | 216.2B | 224.9B | 158.1B |
| Non-Operating | |||||
| Interest Income | 9.6B | 7.3B | 5.7B | 4.6B | 7.9B |
| Interest Expense | 14.3B | 17.0B | 24.4B | 28.5B | 22.6B |
| Net Interest Income | (4.8B) | (9.7B) | (18.7B) | (23.9B) | (14.8B) |
| Other Non-Op Income/Expense | 7.2B | (12.9B) | (44.9B) | (30.9B) | (37.1B) |
| Non-Operating Income (excl Interest) | 14.9B | — | 20.6B | 1.1B | 5.9B |
| EBT (Pre-Tax Income) | 286.3B | 211.0B | 171.3B | 194.0B | 121.0B |
| Income Tax Expense | 51.6B | 22.9B | 30.8B | 28.6B | 19.5B |
| Bottom Line | |||||
| Net Income | 217.0B | 170.5B | 121.3B | 146.2B | 82.8B |
| Earnings from Cont. Ops | 234.6B | 188.1B | 140.4B | 165.4B | 101.6B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 217.0B | 170.5B | 121.3B | 146.2B | 82.8B |
| Per Share | |||||
| Basic EPS | ₩18,519 | ₩13,371 | ₩9,567 | ₩11,522 | ₩6,517 |
| Diluted EPS | ₩18,519 | ₩13,362 | ₩9,567 | ₩11,522 | ₩6,517 |
| Revenue Per Share | ₩128,034 | ₩120,797 | ₩117,932 | ₩117,476 | ₩104,813 |
| Shares | |||||
| Basic Shares Outstanding | 12.9M | 12.8M | 12.7M | 12.7M | 12.7M |
| Diluted Shares Outstanding | 12.9M | 12.8M | 12.7M | 12.7M | 12.7M |
| Profitability Metrics | |||||
| EBITDA | 379.8B | 322.7B | 293.0B | 323.3B | 249.0B |
| D&A | 99.7B | 98.8B | 97.3B | 98.5B | 96.8B |
| EBIT | 280.2B | 223.9B | 195.6B | 223.8B | 152.2B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026